{
  "ticker": "ACQ",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02968360",
  "id": "02968360",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250710",
  "time": "1841",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250710/pdf/06lpjb023wqjbm.pdf",
  "summary": "### **Material Information Summary**  \n\n#### **Investment Update (June 2025) \u2013 Key Data**  \n- **NTA per Share (unaudited):**  \n  - Before taxes: **$1.1143**  \n  - After taxes (excl. unrealised gains tax): **$1.1230**  \n  - After taxes (incl. unrealised gains tax): **$1.1091**  \n- **Market Data:**  \n  - **Share price:** **$0.76** (trading at ~32% discount to post-tax NTA)  \n  - **Market cap:** **$68.1m**  \n  - **Dividend yield:** **7.2%** (based on 5.5c past 12-month dividends)  \n- **Performance vs Benchmark (1-month):**  \n  - **ACQ:** **+4.6%**  \n  - **S&P/ASX Small Ords:** **+0.8%**  \n  - Outperformance driven by **Amplia Therapeutics (+278.8%)** (clinical trial success) and **ZIP Co (+60.9%)** (upgraded EBITDA guidance).  \n- **Portfolio Composition:**  \n  - **Top 10 holdings:** **28.8%** of portfolio (Aroa Biosurgery largest at 3.3%).  \n  - **Unlisted exposure:** **21.1%** of portfolio.  \n  - **Cash:** **7.8%**.  \n\n#### **Dividend Policy**  \n- Targets **\u22655% of post-tax NTA annually**, franked where possible.  \n- Potential **special dividends** if excess franking credits accrue.  \n\n#### **Other Material Points**  \n- **Lonsec \"Recommended\" rating** (as of October 2023).  \n- **Underweight Resources sector** (detractor: Golden Horse Minerals **-10.1%** post-capital raising).  \n\nNo capital-raising, M&A, or liquidity events identified. Primarily a performance/NTA update.",
  "usage": {
    "prompt_tokens": 2592,
    "completion_tokens": 431,
    "total_tokens": 3023,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-10T08:48:47.173886"
}